Navigation Links
KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet
Date:12/2/2009

ST. LOUIS, Dec. 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company ( KVa/KVb) today announced that that it has entered into an employment agreement with Interim President and Chief Executive Officer David A. Van Vliet with a term through December 31, 2011. Mr. Van Vliet has served as Interim President and Chief Executive Officer since December 2008.

The employment agreement provides continuity of senior leadership as the Company seeks to resume the manufacture and distribution of products marketed by its subsidiaries, ETHEX and Ther-Rx, in accordance with its consent decree with the U.S. Food and Drug Administration (FDA).

"This agreement reflects the tremendous job David has done leading KV during a very challenging and critical period and ensures continuity of his effective stewardship as we execute against our consent decree and seek to return to market," said Terry Hatfield, Chairman of KV Pharmaceutical.

"While we still have work to do to achieve success, we are making the kind of progress that has our organization believing we can reach our goals," said Mr. Van Vliet. "Our emphasis on building a culture of compliance, openness, teamwork, and innovation is being embraced and is having a meaningful impact."

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's branded drug subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate Web site at www.kvpharmaceutical.com.

SOURCE KV Pharmaceutical Company


'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends
2. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
3. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
4. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
5. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
7. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
8. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
9. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
10. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
11. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2020)... , ... May 17, 2020 ... ... healthcare professionals, who in collaboration with a physician, can provide primary care, ... clinical diagnosis, therapeutic intervention, and rehabilitation of injuries and medical conditions. Secondary ...
(Date:5/15/2020)... , ... May 15, 2020 , ... ... acquisition of Medication Assisted Recovery Centers (MARC), an office-based opioid treatment (OBOT) program ... Slidell, provide medication-assisted treatment (MAT) and recovery services in a physician’s office setting. ...
(Date:5/14/2020)... ... May 14, 2020 , ... Clear Labs , providers of the only ... round of funding led by Redmile Group, as well as existing investors including Wing ... date, Clear Labs has raised $62M. , In addition to supporting ongoing commercialization ...
Breaking Medicine Technology:
(Date:5/17/2020)... ... 18, 2020 , ... R3 Stem Cell International is now ... There are two program options for patients and their families, which are all ... unclear exactly what causes Autism Spectrum Disorder (ASD), there are several recent clinical ...
(Date:5/16/2020)... ... May 15, 2020 , ... On May 21, T1V will host a webinar featuring ... of USC, and a contributor to CBS news, as we address COVID-19 and the impact ... most parts of the country since March, many questions are left unanswered as we look ...
(Date:5/16/2020)... ... May 16, 2020 , ... Dr. Tomasz Biernacki ... will prevent permanent arthritis from developing. This can keep the foot from being unable ... “It is estimated that the people who develop flat feet and bunion ...
(Date:5/15/2020)... TORONTO (PRWEB) , ... May 15, 2020 , ... Collagen ... 56% in the natural channel alone in 2019, according to a 2020 Nutritional Outlook ... eyes – moving further and further away from the high molecular weight, low-impact products ...
(Date:5/15/2020)... ... 2020 , ... On May 17, World NF Awareness Day, actors, musicians, comedians, ... a benefit to support the Children’s Tumor Foundation and to Make NF Visible. NF, ... nerves throughout the body and affects all ethnicities, races, and genders equally. In addition ...
Breaking Medicine News(10 mins):